Managed Care - November 2008 - (Page RSV2)

SELF-STUDY CONTINUING EDUCATION ACTIVITY Respiratory Syncytial Virus (RSV): Prevention Strategies and the Appropriate Identification of Vulnerable Populations Overview/needs assessment Respiratory syncytial virus (RSV) is a common and easily transmitted disease that affects young children and is the leading cause of hospitalization of infants younger than 1 year of age. It is estimated that in the United States, up to 126,000 infants are hospitalized each year because of severe RSV disease, and that close to 20 percent of these are premature infants. RSV disease is also a risk factor for the development of respiratory ailments and physician-diagnosed asthma in later life. RSV is costly. A single hospitalization can cost more than $5,000 a day for a child in need of respiratory assistance, and the high cost of immunoprophylaxis limits its use to those infants at highest risk of complications from RSV infection. RSV infection also is common among the elderly and the immunocompromised and, together with influenza virus, is the most common cause of hospital admissions for adults with chronic cardiac and pulmonary disorders and acute respiratory failure. This Continuing Medical Education program provides current information on our understanding of RSV seasonality, vulnerable populations, preventive strategies, and the therapeutic approaches available to manage RSV. Target audience This program is targeted to medical directors, physicians, and pharmacists in managed care organizations. Educational objectives After reading this publication, participants will be able to: • Explain the epidemiology, burden of disease, and seasonal and regional variability of RSV. • Discuss the economic impact of RSV on the health care system. • Explain which populations are at high risk of RSV infection and why. • Discuss current and new prophylactic options for managing RSV. • Establish educational initiatives to raise the awareness of parents and health care professionals about the prevention and treatment of RSV. • Assess best practices in a managed care setting for managing RSV, so as to improve outcomes. Method of instruction Participants should read the learning objectives and review the activity in its entirety. After reviewing this activity, submit a completed post-test and evaluation. Upon achieving a passing score of 70 percent or better on the post-test, a statement of credit will be awarded. Accreditation and designation This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the sponsorship of The Chatham Institute. The Chatham Institute is accredited by the ACCME to provide continuing medical education for physicians. The Chatham Institute designates this educational activity for a maximum of 1.50 AMA PRA Category 1 Credits.TM Physicians should claim credit commensurate with the extent of their participation in the activity. The Chatham Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.50 contact hours (0.150 CEU) of continuing education for pharmacists. ACPE Universal Program Number (UPN): 812-000-08-024-H01-P Release Date: Nov. 20, 2008 Expiration Date: Nov. 20, 2009 Medium: Journal supplement Planning committee members Douglas Burgoyne, PharmD, RPh; Michael P. Frogel, MD; Julio A. Ramirez, MD, FACP; Eric A.F. Simões, MD, DCH; Albert Tzeel, MD, MHSA; Steven R. Peskin, MD, MBA, medical director, The Chatham Institute; Katherine T. Adams, editor. Conflict-of-interest policy and disclosures of significant relationships It is the policy of The Chatham Institute to ensure balance, independence, objectivity, and scientific rigor in all of its educational programs. The Chatham Institute requires the disclosure of any significant financial interest or any other relationship a facility member may have with the manufacturer(s) of any commercial product(s) or device(s). Further, faculty members are required to disclose discussion of any offlabel uses in their presentation. Any faculty members not complying with the disclosure policy are not permitted to participate in the educational activity. All program content has been peer reviewed for balance and any potential bias. Peer reviewers of this program have no real or apparent conflicts of interest to report with respect to the content of this publication. The process to resolve conflicts of interest aims to ensure that financial relationships with commercial interests and resultant loyalties do not supersede the public interest in the design and delivery of continuing medical activities for the profession. The faculty of this program and the editorial staff of this monograph have disclosed the following: Michael P. Frogel, MD: grant and research support and speaker’s bureau , MedImmune. Julio Ramirez, MD, FACP: grant and research support from Pfizer, Cubist Pharmaceuticals, Merck & Co., and Wyeth Pharmaceuticals; speaker’s bureau for Pfizer, Cubist Pharmaceuticals, Merck & Co., Ortho-McNeil, and Schering-Plough. Eric S. F. Simões, MD, DCH: Grant and research support and speaker’s Bureau, MedImmune and Abbott. Douglas Burgoyne, Pharm D, RPh: Honoraria from Eli Lilly, GlaxoSmithKline, and Abbott. Albert Tzeel, MD, MHSA; Steven R. Peskin, MD, MBA, The Chatham Institute; and Katherine T. Adams, editor, report no real or apparent conflict of interest with respect to the content of this publication. Program sponsorship and support This activity is sponsored by The Chatham Institute, and is supported by an educational grant from MedImmune. 2 MANAGED CARE / SUPPLEMENT

Table of Contents Feed for the Digital Edition of Managed Care - November 2008

Managed Care - November 2008 Editor’s Memo Contents News and Commentary Legislation & Regulation Letters Medication Management Compensation Monitor Do It Yourself for Less Biomarkers Promise, but Do They Deliver? Oncologists Complain About Drug Payment Consider Blood Pressure Self-Monitoring Q&A: Keep Industry in the Game Formulary Files Plan Watch Tomorrow’s Medicine Outlook Respiratory Syncytial Virus Managed Care Considerations Contents Continuing Education Objectives RSV Disease in the Pediatric Population In the Trenches RSV Infection in the Adult Population Health Plan Medical Director Health Plan Pharmacy Director RSV Issues and Solutions Assessment/Evaluation/Certificate Request Post-Test

Managed Care - November 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.